Skip to content

Category: clinical trial

FDA Committee Unanimously Recommends Approval for Spark’s RPE65 Gene Therapy – Final Decision Due in January 2018

Source: Foundation Fighting Blindness Blog – Eye on the Cure – FDA Committee Unanimously Recommends Approval for Spark’s RPE65 Gene Therapy – Final Decision Due in January 2018 Ashley and Cole Carper traveled from Little Rock, AR, to tell their family’s story at the FDA hearing. Spark Therapeutics has…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial MeiraGTx, a gene-therapy company in London and New York City, has treated its first patient in a gene-therapy clinical trial for people with X-linked retinitis pigmentosa (XLRP) caused by mutations…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Twelve People Receive XLRS Gene Therapy in AGTC’s Clinical Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Twelve People Receive XLRS Gene Therapy in AGTC’s Clinical Trial Applied Genetics Technology Corporation (AGTC) reported that its gene therapy for X-linked retinoschisis (XLRS) has performed encouragingly in a Phase I/II, safety-oriented clinical trial taking place at seven…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

SparingVision Formed to Advance Sight-Saving Protein for RP

Source: Foundation Fighting Blindness Blog – Eye on the Cure – SparingVision Formed to Advance Sight-Saving Protein for RP L to R: Florence Allouche Ghrenassia, PharmD, President, SparingVision; Frédérique Vidal, French Minister of Higher Education, Research and Innovation; José-Alain Sahel, MD, Co-Founder, SparingVision and Fondation Voir & Entendre; David…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Valproic Acid’s Effect Too Small in One-Year Clinical Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Valproic Acid’s Effect Too Small in One-Year Clinical Trial However, researchers identify a potentially powerful endpoint for evaluating emerging therapies in future studies. Results from a clinical trial sponsored by the Foundation Fighting Blindness Clinical Research Institute (FFB-CRI)…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest